M Montero1, M Domínguez, M Orozco-Levi, M Salvadó, H Knobel. 1. Department of Internal Medicine and Infectious Diseases, Hospital del Mar, Autonomous University of Barcelona, Paseo Marítimo 25-29, 08003, Barcelona, Spain. 95422@imas.imim.es
Abstract
BACKGROUND: The incidence of infections caused by multiresistant Pseudomonas aeruginosa (MDRP) is increasing, especially in critically ill patients. The relevance of MDRP in the prognosis of chronic obstructive pulmonary disease (COPD) acute exacerbation in patients admitted to the hospital's general ward is not well known. PATIENTS AND METHODS: Case and control study. Cases were patients admitted for COPD acute exacerbation in which a MDRP was isolated from spontaneous sputum. MDRP was defined as the absence of susceptibility to three or more antibiotic families (betalactams, quinolones, carbapenems and aminoglycosides). Patients currently or previously admitted to the intensive care unit (ICU), who had a recent surgery, neoplasia or immunosuppressive treatment were excluded from the study. Patients from the control group were admitted for COPD acute exacerbation and matched 1:1 with each case-patient in terms of age, sex, date of admission and degree of airway obstruction. Pseudomonas aeruginosa susceptible to all antimicrobials or other microorganisms was isolated from sputum. RESULTS: During the study period (2000-2005), 50 case-patients and 50 controls were included. Crude mortality at 2 years was 60% for the case-patients and 28% for the control group. In the logistic regression analysis adjusted for age, FEV(1) and number of previous hospital admissions, MDRP infection was associated to an increased mortality in comparison to patients without MDRP (OR = 6.2; IC 95%: 1.7-22.1; p < 0.01). CONCLUSIONS: In COPD patients admitted to the general ward, acute exacerbation with MDRP in sputum was associated with higher mortality.
BACKGROUND: The incidence of infections caused by multiresistant Pseudomonas aeruginosa (MDRP) is increasing, especially in critically illpatients. The relevance of MDRP in the prognosis of chronic obstructive pulmonary disease (COPD) acute exacerbation in patients admitted to the hospital's general ward is not well known. PATIENTS AND METHODS: Case and control study. Cases were patients admitted for COPD acute exacerbation in which a MDRP was isolated from spontaneous sputum. MDRP was defined as the absence of susceptibility to three or more antibiotic families (betalactams, quinolones, carbapenems and aminoglycosides). Patients currently or previously admitted to the intensive care unit (ICU), who had a recent surgery, neoplasia or immunosuppressive treatment were excluded from the study. Patients from the control group were admitted for COPD acute exacerbation and matched 1:1 with each case-patient in terms of age, sex, date of admission and degree of airway obstruction. Pseudomonas aeruginosa susceptible to all antimicrobials or other microorganisms was isolated from sputum. RESULTS: During the study period (2000-2005), 50 case-patients and 50 controls were included. Crude mortality at 2 years was 60% for the case-patients and 28% for the control group. In the logistic regression analysis adjusted for age, FEV(1) and number of previous hospital admissions, MDRP infection was associated to an increased mortality in comparison to patients without MDRP (OR = 6.2; IC 95%: 1.7-22.1; p < 0.01). CONCLUSIONS: In COPDpatients admitted to the general ward, acute exacerbation with MDRP in sputum was associated with higher mortality.
Authors: Joanna B Goldberg; Robert E W Hancock; Rebecca E Parales; Joyce Loper; Pierre Cornelis Journal: J Bacteriol Date: 2007-12-28 Impact factor: 3.490
Authors: Fanny W S Ko; Margaret Ip; Paul K S Chan; Joan P C Fok; Michael C H Chan; Jenny C Ngai; Doris P S Chan; David S C Hui Journal: Chest Date: 2007-01 Impact factor: 9.410
Authors: Thomas P Lodise; Christopher D Miller; Jeffrey Graves; Jon P Furuno; Jessina C McGregor; Ben Lomaestro; Eileen Graffunder; Louise-Anne McNutt Journal: Antimicrob Agents Chemother Date: 2006-12-11 Impact factor: 5.191
Authors: Timothy F Murphy; Aimee L Brauer; Karen Eschberger; Phyllis Lobbins; Lori Grove; Xueya Cai; Sanjay Sethi Journal: Am J Respir Crit Care Med Date: 2008-01-17 Impact factor: 21.405
Authors: M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij Journal: Clin Microbiol Infect Date: 2011-11 Impact factor: 8.067
Authors: S Kouda; Y Fujiue; Y Watanabe; M Ohara; S Kayama; F Kato; J Hisatsune; K Tsuruda; A Matsubara; M Doi; M Kuwabara; M Sugai Journal: Infection Date: 2011-04-22 Impact factor: 3.553
Authors: S Marina Casalino-Matsuda; Aisha Nair; Greg J Beitel; Khalilah L Gates; Peter H S Sporn Journal: J Immunol Date: 2015-04-20 Impact factor: 5.422
Authors: Natalia Vasylieva; Seiya Kitamura; Jiexian Dong; Bogdan Barnych; Kelli L Hvorecny; Dean R Madden; Shirley J Gee; Dennis W Wolan; Christophe Morisseau; Bruce D Hammock Journal: Anal Chim Acta Date: 2019-01-09 Impact factor: 6.558
Authors: Christopher D Bahl; Kelli L Hvorecny; Andrew A Bridges; Alicia E Ballok; Jennifer M Bomberger; Kyle C Cady; George A O'Toole; Dean R Madden Journal: J Biol Chem Date: 2014-01-28 Impact factor: 5.157
Authors: Eva Morales; Francesc Cots; Maria Sala; Mercè Comas; Francesc Belvis; Marta Riu; Margarita Salvadó; Santiago Grau; Juan P Horcajada; Maria Milagro Montero; Xavier Castells Journal: BMC Health Serv Res Date: 2012-05-23 Impact factor: 2.655
Authors: Khalilah L Gates; Heather A Howell; Aisha Nair; Christine U Vohwinkel; Lynn C Welch; Greg J Beitel; Alan R Hauser; Jacob I Sznajder; Peter H S Sporn Journal: Am J Respir Cell Mol Biol Date: 2013-11 Impact factor: 6.914